Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC

(AGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Allergan says revenue from aesthetics unit may double by 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2018 | 01:49pm EDT
The Allergan logo is seen in this photo illustration

NEW YORK (Reuters) - Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox.

Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

Chief Commercial Officer Bill Meury said Allergan expects revenue at its medical aesthetics unit to grow to $7 billion to $8 billion. That compares with revenue of $3.8 billion from the business in 2017.

Beyond Botox, the unit includes dermal filler Juvederm, the CoolSculpting fat-freezing systems, and other treatments.

He said the forecast implied an 8 to 10 percent compound annual growth rate.

Meury said the Bonti acquisition would allow the company to market a new "starter toxin." Patients could test drive the treatment, which lasts for two to four weeks, to help them decide if they want to use longer-term Botox.

Shares of Allergan fell 0.9 percent to $188.21 on Friday, while shares of Revance were down 1.1 percent and Evolus fell around 2.5 percent.

(The story corrects Allergan company stock price in final paragraph.)

(Reporting by Michael Erman; Editing by Chizu Nomiyama and Bernadette Baum)

By Michael Erman

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -0.09% 168.94 Delayed Quote.26.40%
EVOLUS, INC. 2.28% 14.33 Delayed Quote.20.42%
ONE STOP SYSTEMS, INC. -3.45% 2.5971 Delayed Quote.33.87%
REVANCE THERAPEUTICS, INC. 15.11% 14.02 Delayed Quote.-30.35%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
06:36aALLERGAN PLC : Submission of Matters to a Vote of Security Holders, Other Events..
AQ
10/14DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan PLC
AQ
10/14ALLERGAN : Shareholders Approve Proposed Acquisition by AbbVie
PU
10/14ALLERGAN : and Molecular Partners Present Late-Breaking Data from Phase 3 Studie..
AQ
10/14ALLERGAN : Form 8.3 - Allergan Plc
DJ
10/11ALLERGAN : and Molecular Partners Present Late-Breaking Data from Phase 3 Studie..
PU
10/11ALLERGAN : Form 8.3 - Allergan Plc
DJ
10/10ALLERGAN : Form 8.3 - Allergan Plc
DJ
10/10ALLERGAN : On World Sight Day, Allergan Launches National Campaign to Raise Awar..
PU
10/09ALLERGAN : Form 8.3 - Allergan Plc
DJ
More news
Financials (USD)
Sales 2019 15 564 M
EBIT 2019 7 141 M
Net income 2019 -3 920 M
Debt 2019 18 536 M
Yield 2019 1,75%
P/E ratio 2019 -18,0x
P/E ratio 2020 63,9x
EV / Sales2019 4,75x
EV / Sales2020 4,49x
Capitalization 55 429 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 182,86  $
Last Close Price 168,94  $
Spread / Highest target 50,9%
Spread / Average Target 8,24%
Spread / Lowest Target -8,25%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer & EVP
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC26.40%55 429
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287